484 related articles for article (PubMed ID: 26852726)
1. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
[TBL] [Abstract][Full Text] [Related]
2. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
3. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
Oldach D; Clark K; Schranz J; Das A; Craft JC; Scott D; Jamieson BD; Fernandes P
Antimicrob Agents Chemother; 2013 Jun; 57(6):2526-34. PubMed ID: 23507282
[TBL] [Abstract][Full Text] [Related]
5. Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial.
Chen MY; McNulty A; Avery A; Whiley D; Tabrizi SN; Hardy D; Das AF; Nenninger A; Fairley CK; Hocking JS; Bradshaw CS; Donovan B; Howden BP; Oldach D;
Lancet Infect Dis; 2019 Aug; 19(8):833-842. PubMed ID: 31196813
[TBL] [Abstract][Full Text] [Related]
6. The role of solithromycin in the management of bacterial community-acquired pneumonia.
Van Bambeke F; Tulkens PM
Expert Rev Anti Infect Ther; 2016; 14(3):311-24. PubMed ID: 26848612
[TBL] [Abstract][Full Text] [Related]
7. Solithromycin: A novel ketolide antibiotic.
Buege MJ; Brown JE; Aitken SL
Am J Health Syst Pharm; 2017 Jun; 74(12):875-887. PubMed ID: 28432048
[TBL] [Abstract][Full Text] [Related]
8. Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R; Popescu M; Gonong JR; Mitha I; Nseir W; Madej A; Kirsch C; Das AF; Garrity-Ryan L; Steenbergen JN; Manley A; Eckburg PB; Tzanis E; McGovern PC; Loh E
N Engl J Med; 2019 Feb; 380(6):517-527. PubMed ID: 30726692
[TBL] [Abstract][Full Text] [Related]
9. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
[TBL] [Abstract][Full Text] [Related]
10. Solithromycin monotherapy for treatment of community-acquired bacterial pneumonia: A meta-analysis of randomised controlled trials.
Wen J; Chen F; Zhao M; Wang X
Int J Clin Pract; 2019 May; 73(5):e13333. PubMed ID: 30810253
[TBL] [Abstract][Full Text] [Related]
11. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
[TBL] [Abstract][Full Text] [Related]
12. Solithromycin for the treatment of community-acquired bacterial pneumonia.
Viasus D; Ramos O; Ramos L; Simonetti AF; Carratalà J
Expert Rev Respir Med; 2017 Jan; 11(1):5-12. PubMed ID: 27753516
[TBL] [Abstract][Full Text] [Related]
13. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
[TBL] [Abstract][Full Text] [Related]
14. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
16. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
17. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
[TBL] [Abstract][Full Text] [Related]
19. Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia.
Lang JE; Hornik CP; Elliott C; Silverstein A; Hornik C; Al-Uzri A; Bosheva M; Bradley JS; Borja-Tabora CFC; Di John D; Mendez Echevarria A; Ericson JE; Friedel D; Gonczi F; Isidro MGD; James LP; Kalocsai K; Koutroulis I; Laki I; Ong-Lim ALT; Nad M; Simon G; Syed S; Szabo E; Benjamin DK; Cohen-Wolkowiez M;
Pediatr Infect Dis J; 2022 Jul; 41(7):556-562. PubMed ID: 35675525
[TBL] [Abstract][Full Text] [Related]
20. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
